Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.

NCT00334295 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Endometrial Carcinoma

Interventions

DRUG: Fulvestrant

Sponsor

AstraZeneca